{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:10:59Z","timestamp":1771063859288,"version":"3.50.1"},"reference-count":15,"publisher":"Portland Press Ltd.","issue":"1","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"abstract":"<jats:p>The pathogenesis of anthrax is such that unless antibiotic treatment is initiated at an early stage in the disease, it is ineffective against the bacteria-induced toxaemia that subverts the immune response, inflicts massive tissue damage and is ultimately the major factor contributing to death during anthrax infection. As current events have demonstrated the feasibility of the use of anthrax as a bioterrorism agent, and exemplified the difficulty of treating the ensuing infection, inhibition of anthrax toxin has become a major focus of research for the design of antitoxin therapeutics. In this issue of Biochemical Journal, Bracci and co-workers describe the discovery by competitive screening of a phage-display library of a peptide inhibitor of anthrax toxin assembly that shows great promise towards the treatment of anthrax.<\/jats:p>","DOI":"10.1042\/bj20060245","type":"journal-article","created":{"date-parts":[[2006,3,15]],"date-time":"2006-03-15T16:56:53Z","timestamp":1142441813000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Peptide inhibitors MAP the way towards fighting anthrax pathogenesis"],"prefix":"10.1042","volume":"395","author":[{"given":"Aimee\u00a0M.","family":"deCathelineau","sequence":"first","affiliation":[{"name":"Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary\u00a0M.","family":"Bokoch","sequence":"additional","affiliation":[{"name":"Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2006,3,15]]},"reference":[{"key":"2021112217204351000_B1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199909093411107","article-title":"Anthrax","volume":"341","author":"Dixon","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"2021112217204351000_B2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10254-004-0028-2","article-title":"Anthrax toxins","volume":"152","author":"Mourez","year":"2004","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"2021112217204351000_B3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","article-title":"Anthrax toxin","volume":"19","author":"Collier","year":"2003","journal-title":"Annu. Rev. Cell. Dev. Biol."},{"key":"2021112217204351000_B4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrd1694","article-title":"The evolving field of biodefence: therapeutic developments and diagnostics","volume":"4","author":"Burnett","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112217204351000_B5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0966-842X(01)02294-6","article-title":"Quickening the pace of anthrax research: three advances point towards possible therapies","volume":"10","author":"Chaudry","year":"2002","journal-title":"Trends Microbiol."},{"key":"2021112217204351000_B6","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/IAI.74.2.1016-1024.2006","article-title":"Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax","volume":"74","author":"Peterson","year":"2006","journal-title":"Infect. Immun."},{"key":"2021112217204351000_B7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.tibs.2004.04.011","article-title":"Stop the killer: how to inhibit the anthrax lethal factor metalloprotease","volume":"29","author":"Montecucco","year":"2004","journal-title":"Trends Biochem. Sci."},{"key":"2021112217204351000_B8","doi-asserted-by":"crossref","first-page":"25990","DOI":"10.1074\/jbc.M301232200","article-title":"Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough","volume":"278","author":"Soelaiman","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2021112217204351000_B9","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1073\/pnas.0306552101","article-title":"Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection","volume":"101","author":"Shen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021112217204351000_B10","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1073\/pnas.85.15.5409","article-title":"Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system","volume":"85","author":"Tam","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021112217204351000_B11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1042\/BJ20051747","article-title":"Stable peptide inhibitors prevent binding of lethal and edema factors to protective antigen and neutralize anthrax toxin in vivo","volume":"395","author":"Pini","year":"2005","journal-title":"Biochem. J."},{"key":"2021112217204351000_B12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1074-5521(03)00094-2","article-title":"Rational design and molecular diversity for the construction of anti-alpha-bungarotoxin antidotes with high affinity and in vivo efficiency","volume":"10","author":"Lozzi","year":"2003","journal-title":"Chem. Biol."},{"key":"2021112217204351000_B13","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nbt1001-958","article-title":"Designing a polyvalent inhibitor of anthrax toxin","volume":"19","author":"Mourez","year":"2001","journal-title":"Nat. Biotechnol."},{"key":"2021112217204351000_B14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/mp050040f","article-title":"Functional characterization of peptide-based anthrax toxin inhibitors","volume":"2","author":"Gujraty","year":"2005","journal-title":"Mol. Pharm."},{"key":"2021112217204351000_B15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nbt0202-118","article-title":"Pinpointing anthrax-toxin inhibitors","volume":"20","author":"Glick","year":"2002","journal-title":"Nat. Biotechnol."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/doi\/10.1042\/BJ20060245\/642405\/bj395e001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/doi\/10.1042\/BJ20060245\/642405\/bj395e001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:49:27Z","timestamp":1637628567000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/395\/1\/e1\/79506\/Peptide-inhibitors-MAP-the-way-towards-fighting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,15]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bj20060245","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,15]]},"article-number":"e1"}}